Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00203372 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)
A Phase 2 study, sponsored by Translational Oncology Research International.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00203372: Completed Phase 2 study, sponsored by Translational Oncology Research International.
NCT00203372 is a Phase 2 study that has completed, run by Translational Oncology Research International. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00203372, a Phase 2 study, has completed, sponsored by Translational Oncology Research International.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of the TAC-bevacizumab combination and investigate whether changes in gene expression, or the expression of specific biomarkers, are either predictive of response to bevacizumab or indicative of response.
Primary Outcome
Patients will be evaluated for adverse events (all grades) at each study visit for the duration of their participation in the study. All AEs should be graded using the NCI--CTCAE, Version 3.0. Patients discontinued from the treatment phase of the study for any reason will be evaluated within 30 days after the decision to discontinue treatment.
Interventions
- DRUG Bevacizumab 7.5 and TAC
- DRUG Placebo 7.5 and Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)
- DRUG Bevacizumab 15 and TAC
- DRUG Placebo 15 and TAC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2005-05 |
| Phase | Phase 2 |
What the finished NCT00203372 record still lists
NCT00203372 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 4 interventions - of which Bevacizumab 7.5 and TAC is the first listed.
NCT00203372 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00203372 about?
NCT00203372 is a clinical study titled "Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)". The purpose of this study is to evaluate the safety of the TAC-bevacizumab combination and investigate whether changes in gene expression, or the expression of specific biomarkers, are either predictive of response to bevacizumab or indicative of response.
What is the current status of trial NCT00203372?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2005-05.
What interventions are being tested in trial NCT00203372?
The interventions under investigation include: Bevacizumab 7.5 and TAC (DRUG), Placebo 7.5 and Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) (DRUG), Bevacizumab 15 and TAC (DRUG), Placebo 15 and TAC (DRUG).
Who is sponsoring clinical trial NCT00203372?
This trial is sponsored by Translational Oncology Research International, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00203372's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia